Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' DEFICIT (Details Narrative)

v2.4.0.6
STOCKHOLDERS' DEFICIT (Details Narrative) (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Nov. 30, 2012
May 09, 2012
Feb. 21, 2012
Feb. 07, 2012
Jun. 30, 2011
May 23, 2011
May 02, 2011
Jan. 31, 2011
Feb. 04, 2010
Equity [Abstract]                      
Authorized capital, common stock 750,000,000                    
Authorized capital, common stock par value $ 0.0001                    
Authorized capital, preferred stock 10,000,000                    
Authorized capital, preferred stock par value $ 0.0001                    
Preferred stock designated as Series A 3,000,000                    
Preferred stock designated as Series D 1,000,000                    
Authorized Series D Preferred Stock     4,000,000                
Conversion of Series D Preferred Stock into the Company's common stock     5                
Series D Preferred Stock affiliated with more than the outstanding shares of common stock     9.99%                
Issuance of Series D Preferred Stock     1,000,000                
Issuance of Series D Preferred Stock Purchase Price     $ 50,000                
Issuance of common stock in connection with the payment of accrued directors' fee                   219,863  
Accrued directors' fee                   10,000  
Value of common shares, per share                   $ 0.045  
Value of common shares                   10,000  
Assigned total principal amount of convertible debentures             125,000     250,000  
Assigned total principal amount of warrants                   5,000,000  
Purchase price of Assigned Securities             125,000     300,000  
Net proceeds from converted common stock and exercised warrants                   125,000  
Issuance of common stock in connection with the conversion of the Assigned Debenture             5,000,000     10,000,000  
Issuance of common stock in connection with the exercise of warrants                   5,000,000  
Fair value of shares issued, per share             $ 0.025     $ 0.025  
Issuance of common stock to Daniel Bleak                 10,000,000    
Five year option to purchase shares of Common Stock                 30,000,000    
Exercise price, per share, for common stock                 $ 0.05    
Mineral cost                 500,000    
Shares of common stock sold               11      
Purchase price of common stock sold, per share               $ 0.05      
Aggregate purchase price of common stock sold               550,000      
Payments made to investors of their investment               1.00%      
Maximum payments made to investors of their investment               5.00%      
Total amount of convertible debentures converted into common stock   325,000       55,000          
Issuance of common stock in connection with the conversion of convertible debentures   13,000,000       2,200,000          
Amount of conversion price for the shares, per share   $ 0.025       $ 0.025          
Issuance of common stock to consultant for consulting and investor relations services rendered   1,000,000                  
Valued common shares at the fair market value, per share   $ 0.13     $ 0.14            
Valued common shares at the fair market value   130,000     3,500,000            
Stock based consulting   130,000                  
Purchased shares of common stock to Mr. Bleak         30,000,000            
Restricted shares of common stock granted to Mr. Bleak as compensation for continued services         25,000,000            
Option to purchase shares of Common Stock                 30,000,000    
Option to purchase shares of Common Stock, per option                 $ 0.05    
Option to purchase shares of Common Stock, total amount                 1,494,596    
Volatility rate                 25900.00%    
Risk-free interest rate       0.77%         1.96%   2.29%
Stock-based compensation expense related to stock options $ 41,516 $ 332,132